Plain-English summary
Court considers whether marketing and public info suffice to plead induced infringement for carved-out generics
The Court is reviewing whether statements by a generic drugmaker — calling its product a “generic version” and citing public information about a branded drug — can, together with a label that carves out a patented use, support a claim that the generic induced infringement of that patented use. The case is set for argument and remains pending.
Why this matters
The decision will affect how generic drugmakers can market products that intentionally exclude patented uses and how patent owners can protect method-of-use patents. A broad rule for induced infringement could expose generic companies, distributors, and possibly others in the supply chain to more patent litigation; a narrow rule could limit remedies for patent owners and shape drug labeling and marketing practices.
Who may feel it
- Generic drug manufacturers and their marketers
- Brand-name pharmaceutical companies with method-of-use patents
- Doctors, pharmacists, and hospitals prescribing or dispensing generics
- Patients who use generic drugs
- Patent holders, patent litigators, and the pharmaceutical industry at large
Key questions
- When a generic drug’s FDA-approved label deliberately carves out a patented use, can allegations that the maker called its product a “generic version” and cited public information about the branded drug (such as sales or prescribing data) —